CAR-T Cell Therapies-unique spectrum of toxicities

[HopingForTheBest1]

Identifying and Managing Delayed Adverse Events Associated With CAR T-Cell Therapy

Source: Current and Emerging CAR T-Cell Therapies in Cancer Care

Caron A. Jacobson, MD

Released: August 5, 2021

Although CAR T‑cell therapies can offer significantly improved outcomes for many patients with high‑risk leukemias, lymphomas, and myelomas who lack other treatment options, these products can be associated with a unique spectrum of toxicities that physicians and nurses must be adept at managing. The most worrisome adverse events of CAR T‑cell therapy—cytokine-release syndrome and neurologic toxicity—tend to occur in the first 1‑4 weeks following infusion. This is typically when the patient is still in close proximity to the CAR T‑cell treatment center and able to seek care from experienced physicians and hospital staff. But, as patients transition from their CAR T‑cell treatment center back to their local and community oncology clinic, there are notable potential delayed adverse events that their oncologists need to keep in mind.

[Ahk1]

Wish you best of luck in your new treatments.

[HopingForTheBest1 in reply to Ahk1]

Thanks. My new treatment, which I started last week, is not a CAR-T therapy. I posted this for general info.

[Shooter1]

Looked at CAR-T but don't fit right now... Taking Poveng right now... Best of luck with your trial, enzalutamide by itself made me an invalid at full dose...